FIELD: medicine.
SUBSTANCE: invention relates to medicine. Disclosed is a pharmaceutical composition for treating cancer, comprising one or more miRNA selected from a group consisting of miR-3670 and miR-8078, where miR-3670 includes a double-stranded RNA presented by nucleotide sequences SEQ ID NO: 35 and SEQ ID NO: 36, and miR-8078 comprises a double-stranded RNA presented by nucleotide sequences SEQ ID NO: 65 and SEQ ID NO: 66.
EFFECT: invention provides inhibition of proliferation and inducing apoptosis of cancer cells.
4 cl, 8 dwg, 3 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF microRNA BIOGENESIS IN EXOSOMES FOR DIAGNOSTICS AND TREATMENT | 2014 |
|
RU2644247C2 |
| ANTICANCER RNA VACCINES | 2017 |
|
RU2768829C2 |
| COMPOSITION FOR REDUCING HAIR GRAYING, STIMULATING HAIR GROWTH AND/OR PREVENTING OR REDUCING HAIR LOSS, CONTAINING DOUBLE-STRANDED MCRNA AS ACTIVE INGREDIENT | 2022 |
|
RU2823325C1 |
| DOUBLE-STRANDED RNA MOLECULE FOR MIR-34A ACTIVITY IN CELL | 2012 |
|
RU2615117C2 |
| COMPOSITION FOR TREATMENT OF CANCER ASSOCIATED WITH HPV INFECTION | 2013 |
|
RU2636003C2 |
| GENE INVOLVED IN IMMORTALISATION OF HUMAN CANCER CELL AND USE THEREOF | 2007 |
|
RU2449016C2 |
| NOTCH 1-SPECIFIC SIRNA MOLECULES | 2014 |
|
RU2651493C2 |
| COMPOSITION FOR TREATING CANCER ASSOCIATED WITH HPV INFECTION | 2017 |
|
RU2664466C1 |
| SORAFENIB-BASED COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA | 2022 |
|
RU2800071C1 |
| ONCOLYTIC HSV-VECTOR | 2014 |
|
RU2719190C2 |
